Biotech startup Imperagen is making serious moves in enzyme engineering after locking down a £5 million seed round, roughly $6.7 million, to push quantum physics and artificial intelligence into the biotech space.
The funding round was led by PXN Ventures, with IQ Capital and Northern Gritstone also jumping in. The Cambridge-linked investment signals growing confidence in deep tech startups combining AI biotech tools with quantum-based approaches to protein and enzyme design.
Enzyme engineering has been a hot space for AI-driven biotech investment, with companies racing to crack faster, more precise biological design methods. Imperagen is betting that layering quantum physics on top of AI models gives it an edge that traditional computational biology simply cannot match.
For a seed round, £5 million is a solid runway, and with backers like IQ Capital already known for deep tech bets, Imperagen has the right people in its corner.
Watch this one closely.
Source: Original Article
